AbbVie Gains on Expanding Oncology Portfolio and Rinvoq's $3.7 Billion H1 Sales as $1.16 Billion Volume Ranks 69th

Abbvie (ABBV) rose 0.53% on August 22, 2025, with a trading volume of $1.16 billion, ranking 69th in market activity. The stock's performance was influenced by its expanding oncology portfolio, which generated $3.3 billion in combined revenue during the first half of 2025. Double-digit growth in recently acquired therapies Elahere and Epkinly, along with ongoing sales of Venclexta, offset declining Imbruvica revenue amid competitive pressures. The company's pipeline includes two commercial antibody-drug conjugates (ADCs) and multiple next-generation ADCs in late-stage development, positioning it for long-term growth in the oncology sector.

Recent clinical progress for Rinvoq, a key immunology drug, further bolstered investor confidence. Positive phase III results for severe alopecia areata demonstrated 45.2% and 55% scalp hair coverage at 24 weeks for 15mg and 30mg doses, respectively. With $3.7 billion in H1 2025 sales (up 49% year-over-year), Rinvoq is on track to reach $8 billion in annual revenue. The drug's potential expansion into vitiligo, hidradenitis suppurativa, and systemic lupus erythematosus could add $2 billion in peak-year sales. However, competition remains intense in key indications like alopecia areata, where established rivals such as Eli Lilly and Pfizer are also active.

The strategy of buying the top 500 stocks by daily trading volume and holding them for one day from 2022 to now delivered moderate returns. The CAGR was 6.98%, with a maximum drawdown of 15.59% during the backtest period. The strategy demonstrated steady growth over time, making it a robust choice for investors seeking consistent returns. However, the significant drawdown in mid-2023 highlights the importance of risk management in high-volume trading strategies.